1 / 29

Biomarkers markets opportunities and forecast 2013-2020

Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.

alliedmarketresearch
Télécharger la présentation

Biomarkers markets opportunities and forecast 2013-2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Allied Market Research Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 - 2020 Buy Now Request Sample Published Date: 9-Dec-2013 Single User License: US $ 4515 Multi User License: US $ 7515 Corporate License: US $ 10515 151 Pages Report Report Description : Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.

  2. Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 - 2020

  3. Description Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. Biomarkers are novel diagnostic solutions and advancement in it its development and understanding of human genome promotes its application in diagnosis of disease on molecular basis. Pharmaceutical companies which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, educational institute and these companies are also increasing their investments in research and development. The global market for diagnostic biomarker expected to reach about $30.6 billion in 2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.

  4. SCOPE Global diagnostic Biomarker report segments the market in three categories; market by technologies, market by services, and market by diseases. These markets are expected to show elevated growth in future as biomarkers are providing diagnostic service for complex disease. As it is non-invasive procedure it motivates the use of biomarkers than conventional diagnostic applications. This report focuses on key factors impacting the diagnostic biomarker market used in risk assessment, molecular diagnostics, disease diagnosis, drug discovery and development, drug formulation, forensic applications and others. Diagnostic biomarker and its applications in emerging segments of omics, imaging technologies, personalized medicine, and bioinformatics are all discussed in detail.  

  5. Key Deliverables Biomarkers of disease are majorly covered by oncology, cardiovascular and Neurology disease. Oncology biomarkers are covering more market share as compared to other disease biomarkers. Other biomarker are facing some ethical and technical problem such complex sample preparation process. Biomarkers in service has open a new market for sample preparation for disease diagnosis which enables clinicians to save time required for preparing sample to conduct diagnostic test. Biomarkers are also resolving drug validation problem by analyzing viability of drug discovered by pharmaceutical research. The key players in this market that are also profiled in the report include Roche Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), AushonBioSystem Inc. (M.A.), Epistem Ltd.(U.K.), G.E. Healthcare Inc.(U.K).

  6. Key Benefits of Report • Assessment and ranking the factors that favour the market growth and those factors which act as a hindrance for the growth of the market • The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011 and 2012 • The report identifies and analyses top investment pockets and top winning strategies for diagnostic biomarker market • The report analyses the various strategies adopted by some of the key companies in the market • The report tracks and analyses key innovations and patents for biomarkers in the last five years

  7. Table of content 1.  Introduction 2.Executive Summary 3.Market Overview 4.Global Diagnostic Biomarkers Market by Types 5. Global Diagnostic Biomarkers Market by Applications 6. Global Diagnostic Biomarkers Market by Services 7. Global Diagnostic Biomarkers Market by Geography 8. Competitive Landscape 9. Company Profile

  8. Chapter 1    Introduction 1.1Scope and Coverage 1.2Report Description Chapter 2    Executive Summary 2.1Biomarker Diagnosis Vs. Conventional Diagnosis 2.2Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development? Chapter 3    Market Overview 3.1Key Application of Diagnostic Biomarkers in Top Technologies 3.1.1Omics Technology 3.1.1.1    Applications of Omics Technology 3.1.1.1.1  Lung Disease Identification 3.1.1.1.2  Quantifying Abnormalities 3.1.1.1.3  Genetic Trait Diagnosis 3.1.1.1.4  Analyzing Drug Efficiency 3.1.1.1.5  Functional Food Development 3.1.1.1.6Pharmacogenomics 3.1.1.1.7Drivers

  9. Continue … 3.1.1.1.8  Restraints 3.1.1.1.8.1 Lengthy Process 3.1.1.1.8.2 Ethical Problems 3.1.1.1.8.3 Sample Collection 3.1.1.1.8.4 Gene Expression 3.1.1.1.8.5 Inefficiency in Pre-Disease Identification 3.1.2   Imaging Technology 3.1.2.1    Application of Diagnostic Imaging Technology 3.1.2.2    Drivers 3.1.2.2.1  Faster Test Result 3.1.2.2.2  Improved Nursing Services 3.1.2.2.3  Noninvasive Technique 3.1.2.3    Restraints 3.1.2.3.1  Radiation Effect 3.1.2.3.2  Complex Process 3.1.2.3.3  Genetic Variation 3.1.2.4Trends

  10. Continue … 3.1.3   Bioinformatics 3.1.3.1    Applications of Bioinformatics 3.1.3.2    Drivers 3.1.3.2.1  Open Source of Information 3.1.3.2.2  Relevant Information 3.1.3.2.3  Forecasting of Information 3.1.3.3    Restraints 3.1.3.3.1  Difficulty in Practical Application 3.1.3.3.2  Over-Fitting 3.1.3.3.3  Complex Operation Process 3.1.3.3.4  Security Issue 3.1.3.3.5  Costly Management 3.1.3.3.6  Virtual Storage 3.1.4   Personalized Medicines 3.1.4.1    Drivers 3.1.4.1.1  Unique Solution 3.1.4.1.2  Minimal Invasive 3.1.4.1.3  Reduction in Failure 3.1.4.1.4  Effective Prescription

  11. Continue … 3.1.4.2    Restraints 3.1.4.2.1  Need Specialized Setup for Treatment 3.1.4.2.2  Liability Issue 3.1.4.2.3  Ethical Question 3.1.5   Others (Nutritional Technology) 3.2      Importance of Non-Invasive Diagnostics 3.3      Key Advantages of Dm 3.4      Regulatory Scenario 3.5      Reimbursement Issues 3.6      Key Patents and Analysis 3.7      Top Ten Factors Impacting DBM Market 3.7.1   Non-Invasive Technique 3.7.2   Drug Discovery and Development 3.7.3   Cost Effective Tool for Diagnosis 3.7.4   Multi-Marker Application 3.7.5   Accuracy and Reliability 3.7.6   Ethical Issues 3.7.7   Gene Level Diagnosis

  12. Continue … 3.7.8   Complex Processes 3.7.9   Government Regulations 3.7.10 Reimbursement Issues 3.8      Top Investment Pockets 3.9      Market Intelligence 3.9.1   Top Three Winning Strategies 3.9.1.1    Product Launch 3.9.1.2    Collaboration and Agreement 3.9.1.3    Merger and Acquisition 3.10    Market Dynamics 3.10.1 Drivers 3.10.1.1 Cost Effective 3.10.1.2 Non-Invasive 3.10.1.3 Accuracy in Result 3.10.1.4 Assistant in Clinical Trials 3.10.1.5 Multi-Marker Application 3.10.1.6 Gene Level Diagnosis 3.10.2 Restrains 3.10.2.1 Government Regulation 3.10.2.2 Ethical Problems

  13. Continue … 3.10.2.3 Conformation in Result 3.10.2.4 Complex Process 3.10.3 Opportunity 3.10.3.1 Local Market 3.10.3.2 Personalized Medicine 3.10.3.3 Tissue Specific Treatment Chapter 4    Global Diagnostic Biomarker Market by Types 4.1      Biomarker of Exposure 4.2      Biomarkers of Disease Chapter 5    Global Diagnostic Biomarker Market by Applications 5.1      Risk Assessment 5.1.1   Applications 5.1.1.1    Oncology Treatment 5.1.1.2    Cardiovascular Treatment 5.1.2   Drivers 5.1.2.1    Forecasting of Abnormal Conditions 5.1.2.2    Cost Effective

  14. Continue … 5.1.3   Restraints 5.1.3.1    Government Regulations 5.1.3.2    Ethical Issues 5.2      Development of Molecular Diagnostic 5.2.1   Application 5.2.1.1    Prenatal Diagnostics 5.2.1.2    Human Clinical Molecular Diagnostic Testing 5.2.1.3    Veterinary Molecular Diagnostic Testing 5.2.1.4    Identity Testing 5.2.1.5Histocompatibility Testing 5.2.2   Drivers 5.2.2.1    Uniformity in Test Result 5.2.2.2    Cost Effective 5.2.2.3    Fast Result 5.2.2.4    More Profitable 5.2.2.5    Automation 5.2.3   Restraints 5.2.3.1    Not Applicable for Twins Genomes 5.2.3.2    Government Regulations 5.2.3.3    Ethical Issues

  15. Continue … 5.3      Disease Diagnosis 5.3.1   Oncology 5.3.1.1    Drivers 5.3.1.2    Restraints 5.3.1.2.1  Complex Process 5.3.1.2.2  Conformation in Result 5.3.1.2.3  Used for Early Diagnosis Only 5.3.2   Cardiology 5.3.2.1    Application 5.3.2.2    Drivers 5.3.2.2.1  Cost Effective 5.3.2.2.2  Tissue Specific 5.3.2.2.3  Accurate Result 5.3.2.3    Restraints 5.3.2.3.1  Loss of Specificity 5.3.2.3.2  Low Specificity 5.3.2.3.3  Low Sensitivity 5.3.3   Neurology 5.3.3.1    Application 5.3.3.2Drivers

  16. Continue … 5.3.3.2.1  Relevant Information 5.3.3.2.2  Efficient Diagnosis 5.3.3.2.3  Assistant in Clinical Trials 5.3.3.3    Restraints 5.3.3.3.1  Complex Process 5.3.3.3.2  Chromosomal Variation 5.3.3.3.3  Hurdles in Tracking 5.3.3.4    Alzheimer’s 5.3.3.5    Multiple Sclerosis 5.3.3.6    Parkinson's Disease 5.3.3.7    Others (Renal Diseases, Urinal Disease) 5.4      Drug Discovery and Development 5.4.1   Application 5.4.2   Drivers 5.4.2.1    Increased Efficiency 5.4.2.2    High Quality Support 5.4.2.3    Cost Effective 5.4.2.4    Collaboration for Novel Development 5.4.3   Restraints 5.4.3.1    Drug Metabolism

  17. Continue … 5.4.3.2    Stability of Biomarkers 5.4.3.3    Complex Process 5.5      Drug Formulation 5.5.1   Application 5.5.2   Drivers 5.5.3   Restraint 5.6      Forensic Application 5.7      Others (Dna Fingerprinting and Others) 5.7.1   Blood Alcohol Concentration Biomarker 5.7.2DnaFingerprinting Chapter 6    Global Diagnostic Biomarker Market by Services 6.1      Sample Preparation 6.1.1   Application 6.1.1.1    Biological Mass Spectrometry 6.1.2   Drivers 6.1.2.1    Cost Effective 6.1.2.2    Sample Rigidity 6.1.2.3    Efficient Forensic Studies 6.1.3   Restraints

  18. Continue … 6.1.3.1    Complex Structure 6.1.3.2    Lack of Effectiveness 6.1.3.3    Extensive Fractionation 6.1.3.4    Loss of Biological Compounds 6.2      Assay Development 6.2.1   Application 6.2.1.1    Clinical Trials 6.2.1.2    Drug Development and Validation 6.2.1.3    Others 6.2.2   Drivers 6.2.2.1    Accuracy 6.2.2.2    Cost Effective 6.2.2.3    Timely Result 6.2.3   Restraints 6.2.3.1    Complexity in Technique 6.2.3.2    Tissue Specific 6.3      Biomarker Validation and Testing 6.3.1   Drivers 6.3.1.1    Reduce Failure Rate 6.3.2   Restraints

  19. Continue … 6.3.2.1    Clinical Errors 6.3.2.2    Time Consuming 6.4      Other Services Chapter 7    Global Diagnostic Biomarker Market by Geography 7.1      North America 7.2      Europe 7.3      Asia-Pacific 7.4      Row (Rest of World) Chapter 8    Competitive Landscape 8.1      Product Launch 8.1.1   Recent Development 8.2      Collaboration and Partnership 8.2.1   Recent Development 8.3      Clearance and Approval 8.3.1   Recent Development 8.4      Mergers and Acquisition 8.4.1   Recent Development

  20. Chapter 9    Company Profile 9.1      Abbott Laboratories, Inc. 9.1.1   Company Overview 9.1.2   Company Snapshot 9.1.3   Business Performance 9.1.4   Strategic Moves and Developments 9.1.4.1    Principal Strategies 9.1.4.2    Secondary Strategies 9.1.5Swot Analysis & Strategic Conclusions 9.2      Agilent Technologies Inc. 9.2.1   Company Overview 9.2.2   Company Snapshot 9.2.3   Business Performance 9.2.4   Strategic Moves and Developments 9.2.4.1    Primary Strategies 9.2.4.2    Secondary Strategies 9.2.5Swot Analysis & Strategic Conclusions 9.3AushonBiosystem 9.3.1   Company Profile 9.3.2   Company Snapshot 9.3.3   Strategic Moves and Developments 9.3.3.1    Primary Strategies

  21. Continue … 9.3.3.2    Secondary Strategies 9.3.4Swot Analysis & Strategic Conclusions 9.4      Bio-Rad Laboratories 9.4.1   Company Profile 9.4.2   Company Snapshot 9.4.3   Business Performance 9.4.4   Strategic Moves and Developments 9.4.4.1    Primary Strategies 9.4.4.2    Secondary Strategies 9.4.5Swot Analysis & Strategic Conclusions 9.5      Eisai Co. Ltd. 9.5.1   Company Profile 9.5.2   Company Snapshot 9.5.3   Business Performance 9.5.4   Strategic Moves and Developments 9.5.4.1    Primary Strategies 9.5.4.2    Secondary Strategies 9.5.5Swot Analysis & Strategic Conclusions

  22. Continue … 9.6Epistem Ltd. 9.6.1   Company Profile 9.6.2   Company Snapshot 9.6.3   Business Performance 9.6.4   Strategic Moves and Developments 9.6.4.1    Primary Strategies 9.6.4.2    Secondary Strategies 9.6.5Swot Analysis & Strategic Conclusions 9.7Ge Healthcare 9.7.1   Company Profile 9.7.2   Company Snapshot 9.7.3   Business Performance 9.7.4   Strategic Moves and Developments 9.7.4.1    Principle Strategies 9.7.4.2    Secondary Strategies 9.7.5Swot Analysis & Strategic Conclusions 9.8      Roche Diagnostics Limited 9.8.1   Company Profile 9.8.2   Company Snapshot

  23. Continue … 9.7.3   Business Performance 9.7.4   Strategic Moves and Developments 9.7.4.1    Principle Strategies 9.7.4.2    Secondary Strategies 9.7.5Swot Analysis & Strategic Conclusions 9.8      Roche Diagnostics Limited 9.8.1   Company Profile 9.8.2   Company Snapshot 9.8.3   Business Performance 9.8.4   Strategic Moves and Developments 9.8.4.1    Principal Strategies 9.8.4.2    Secondary Strategies 9.8.5Swot Analysis & Strategic Conclusions 9.9      Siemens AG 9.9.1   Company Profile 9.9.2   Company Snapshot 9.9.3   Business Performance

  24. Continue … 9.9.4   Strategic Moves and Developments 9.9.4.1    Primary Strategies 9.9.4.2    Secondary Strategies 9.9.5Swot Analysis & Strategic Conclusions 9.10    Thermo Fisher Scientific Inc. 9.10.1 Company Profile 9.10.2 Company Snapshot 9.10.3 Business Performance 9.10.4 Strategic Moves and Developments 9.10.4.1 Primary Strategies 9.10.4.2 Secondary Strategies 9.10.5 Swot Analysis & Strategic Conclusions

  25. Introduction   Scope of the report of the Market Report Report Description

  26. The geographic analysis is based on North America., Europe, Asia-Pacific and Rest of the World. • Rest Of The World (ROW) • Europe • Asia-Pacific (APAC)

  27. Topics Covered in Company Profiles

  28. Top Market Players • Abbott Laboratories Inc. • Agilent Technologies Inc. • AushonBiosystem • Bio-Red laboratories • Eisai Co. Ltd • Epistem Ltd • Ge HealthCare • Roche Diagnostics Limited • Siemens AG • Thermo Fisher Scientific Inc.

  29. Visit Website Connect with us Linked In Face Book Twitter Google +

More Related